chondroitin-sulfates and dimethyl-sulfone

A large number of dietary supplements are promoted to patients with osteoarthritis and as many as one third of those patients have used a supplement to treat their condition. Glucosamine-containing supplements are among the most commonly used products for osteoarthritis. Although the evidence is not entirely consistent, most research suggests that glucosamine sulfate can improve symptoms of pain related to osteoarthritis, as well as slow disease progression in patients with osteoarthritis of the knee. Chondroitin sulfate also appears to reduce osteoarthritis symptoms and is often combined with glucosamine, but there is no reliable evidence that the combination is more effective than either agent alone. S-adenosylmethionine may reduce pain but high costs and product quality issues limit its use. Several other supplements are promoted for treating osteoarthritis, such as methylsulfonylmethane, Harpagophytum procumbens (devil's claw), Curcuma longa (turmeric), and Zingiber officinale (ginger), but there is insufficient reliable evidence regarding long-term safety or effectiveness.

Topics: Anti-Inflammatory Agents; Chondroitin Sulfates; Curcuma; Dietary Supplements; Dimethyl Sulfoxide; Glucosamine; Harpagophytum; Humans; Osteoarthritis; Phytotherapy; Plant Preparations; S-Adenosylmethionine; Sulfones; Treatment Outcome; Zingiber officinale

The purpose of this study was to compare clinical outcomes obtained with the use of glucosamine, chondroitin sulfate, and methylsulfonylmethane (GCM) supplementation after arthrocentesis plus intraarticular hyaluronic acid (HA) injection. A randomized clinical trial was implemented with adult participants with TMJ-OA who were referred to the author's clinic between February 2014 and May 2015. The sample was entirely composed of patients with TMJ-OA who were treated randomly with a one-session arthrocentesis plus intraarticular HA injection only (control group), or an initial one-session arthrocentesis plus intraarticular HA injection followed by 3 months of GCM supplementation (study group). The predictor variable was management (treatment) technique. The outcome variables were visual analog scale evaluations (masticatory efficiency, pain complaint, joint sound) and mandibular mobility (maximal interincisal opening [MIO], and lateral and protrusive motions of the mandible). The outcome variables were recorded preoperatively and 12 months postoperatively. Thirty-one participants were enrolled in the study. Five were lost during follow-up. The final study sample consisted of 26 participants (age 28.35 ± 10.85 y): 14 in the control group (age 28.71 ± 10.94 y); and 12 in the study group (age 27.92 ± 11.20 y). Pain complaints (p < 0.001) and joint sounds (p = 0.030 for the control group; p = 0.023 for the study group) showed statistically significant decreases. Masticatory efficiency (p < 0.001 for the control group; p = 0.040 for the study group) and lateral mandibular motion (p = 0.040 for the control group; p = 0.004 for study group) showed statistically significant increases in both groups, whereas MIO and protrusive mandibular motion showed no significant changes in either group (p > 0.05). After estimating the differences between the follow-up and baseline outcomes, the mean changes in the primary outcome variables (VAS scores, MIO, and mandibular motion) showed no statistically significant differences between the two groups (p > 0.05). Progressions (reparative remodeling) of hard-tissue TMJ structures were observed on CBCT scans of some participants in both groups. These findings suggested that the use of GCM supplementation after arthrocentesis plus intraarticular HA injection produced no additional clinical benefits or improvements for patients with TMJ-OA compared with arthrocentesis plus intraarticular HA injection alone.

Topics: Adolescent; Adult; Arthrocentesis; Chondroitin Sulfates; Dietary Supplements; Dimethyl Sulfoxide; Glucosamine; Humans; Hyaluronic Acid; Injections, Intra-Articular; Osteoarthritis; Range of Motion, Articular; Sulfones; Temporomandibular Joint; Temporomandibular Joint Disorders; Treatment Outcome; Young Adult

Glucosamine, chondroitinsulfate are frequently used to prevent further joint degeneration in osteoarthritis (OA). Methylsulfonylmethane (MSM) is a supplement containing organic sulphur and also reported to slow anatomical joint progressivity in the knee OA. The MSM is often combined with glucosamine and chondroitin sulfate. However, there are controversies whether glucosamine-chondroitin sulfate or their combination with methylsulfonylmethane could effectively reduce pain in OA. This study is aimed to compare clinical outcome of glucosamine-chondroitin sulfate (GC), glucosamine-chondroitin sulfate-methylsulfonylmethane (GCM), and placeboin patients with knee osteoarthritis (OA) Kellgren-Lawrence grade I-II.. a double blind, randomized controlled clinical trial was conducted on 147 patients with knee OA Kellgren-Lawrence grade I-II. Patients were allocated by permuted block randomization into three groups: GC (n=49), GCM (n=50), or placebo (n=48) groups. GC group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate + 500 mg of saccharumlactis; GCM group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate + 500 mg of MSM; while placebo group received three matching capsules of saccharumlactis. The drugs were administered once daily for 3 consecutive months VAS and WOMAC scores were measured before treatment, then at 4th, 8th and 12th week after treatment.. on statistical analysis it was found that at the 12th week, there are significant difference between three treatment groups on the WOMAC score (p=0.03) and on the VAS score (p=0.004). When analyzed between weeks, GCM treatment group was found statistically significant on WOMAC score (p=0.01) and VAS score (p<0.001). Comparing the score difference between weeks, WOMAC score analysis showed significant difference between GC, GCM, and placebo in week 4 (p=0.049) and week 12 (p=0.01). In addition, VAS score also showed significant difference between groups in week 8 (p=0.006) and week 12 (p<0.001).. combination of glucosamine-chondroitinsulfate-methylsulfonylmethane showed clinical benefit for patients with knee OAK ellgren-Lawrence grade I-II compared with GC and placebo. GC did not make clinical improvement in overall groups of patients with knee OA Kellgren Lawrence grade I-II.

Topics: Anti-Inflammatory Agents; Chondroitin Sulfates; Dietary Supplements; Dimethyl Sulfoxide; Double-Blind Method; Drug Therapy, Combination; Female; Glucosamine; Humans; Male; Middle Aged; Osteoarthritis, Knee; Sulfones; Visual Analog Scale

To study the clinical efficacy and safety of the combined medication ARTRA MSM FORTE (400 mg chondroitin sulfate, 500 mg glucosamine hydrochloride, 300 mg methylsulfonylmethane (MSM), and 10 mg sodium hyaluronate calculated with reference to hyaluronic acid) in patients with knee osteoarthritis (OA).. The study enrolled 100 patients with Kellgren-Lawrence grades 2-3 knee OA with obvious pain syndrome (pain intensity scores on a visual analog scale (VAS)) equal or greater than 40 mm during walking. The patients were examined monthly; changes in WOMAC index scores, Get-Up and Go test results, the efficiency of therapy in the opinion of a physician and a patient, and quality of life according to the EQ-5D questionnaire were estimated. They were randomized into 2 groups: 1) 50 patients took ARTRA MSM as 2 tablets daily for one month, then 1 tablet daily; 2) 50 received ARTRA in accordance with the same scheme. Clinical examination was performed before and at 30, 60, 90 and 120 days of the study.. All the 100 patients completed treatment. Analysis of the results showed a significant decrease in pain on VAS in both groups. Reduced pain intensity was observed by the end of the first month of therapy and remained throughout the follow-up. Both medications diminished stiffness just after a month of therapy. They alleviated joint function and reduced total WOMAC scores at Visit 2. Analysis of Get-Up and Go test results indicated significantly less spent time in both groups; however, these differences reached the statistical significance in the ARTRA MSM group just at Visit 2 and in the ARTRA group only at Visit 3. The effect ARTRA MSM occurred more rapidly. This was confirmed by the patient and physician evaluations of the efficiency of treatment, which indicated that its positive effect occurred more rapidly in the ARTRA MSM group (p=0.02). Estimation of EQ-5D scores also showed positive results: there was a significant improvement of these indicators in the two compared groups at Visit 3. Both medications were very well tolerated and caused no adverse reactions; therapy was not discontinued.. ARTRA MSM is rapider in its effect: a significant improvement in Get-Up and Go test results and patient and physician evaluations of the efficiency of treatment. Additional interviews of the patients taking ARTRA MSM demonstrated that 36 (72%) of them reported a prompter pain relief than the ARTRA-treated patients. ARTRA MSM may be recommended for the treatment of OA in clinical practice.. Цель исследования. Оценка клинической эффективности и безопасности комбинированного препарата АРТРА MСM ФОРТЕ (400 мг хондроитина сульфата, 500 мг глюкозамина гидрохлорида, 300 мг метилсульфонилметана, 10 мг гиалуроната натрия в пересчете на гиауроновую кислоту) у пациентов с остеоартрозом (ОА) коленного сустава (КС). Материалы и методы. В исследование включили 100 пациентов с ОА КС II-III стадии по Kellgren-Lawrence, с выраженным болевым синдромом (интенсивность боли при ходьбе 40 мм и более по визуальной аналоговой шкале - ВАШ). Больных осматривали ежемесячно, оценивали динамику индекса WOMAC, тест 'встань и иди', эффективность терапии по мнению врача и пациента, качество жизни по анкете EQ-5D. Пациентов рандомизированно разделили на 2 группы: 50 человек получали препарат АРТРА MСM по 2 таблетки в сутки в 1-й месяц, затем по 1 таблетке в день; 50 человек - препарат АРТРА по той же схеме. Клиническое обследование пациентов проводили в начале исследования, на 30, 60, 90 и 120-й дни от начала исследования. Результаты. Все 100 больных закончили лечение. Анализ результатов показал достоверное снижение боли по ВАШ в обеих группах. Уменьшение интенсивности боли отмечено к концу 1-го месяца терапии, оно сохранялось весь период наблюдения. Оба препарата уменьшали скованность уже через 1 мес терапии. По влиянию на функциональное состояние суставов и суммарный индекс WOMAC оба препарата показали уменьшение показателей со второго визита. Анализ теста 'встань и иди' показал достоверное уменьшение затрачиваемого времени в обеих группах, однако в группе препарата АРТРА MСM эти различия достигали статистической значимости уже на втором визите, а в группе препарата АРТРА - только на третьем визите. Препарат АРТРА MСM обеспечил более быстрое наступление эффекта. Это подтверждают и оценки эффективности лечения, проводимые пациентом и врачом; оценки показали более быстрое наступление положительного эффекта в группе препарата АРТРА MСM (р=0,02). При оценке EQ-5D также получены положительные результаты: достоверное улучшение данных показателей наблюдалось с третьего визита в обеих сравниваемых группах. Переносимость обоих препаратов была очень хорошей, нежелательных явлений, потребовавших отмены терапии, не отмечено. Заключение. Препарат АРТРА МСМ обеспечивает более быстрое развитие эффекта: достоверное улучшение результатов теста 'встань и иди' и оценка эффективности лечения врачом и пациентом. При дополнительном опросе больных, принимавших препарат АРТРА МСМ, 36 (72%) отме

Topics: Aged; Anti-Inflammatory Agents; Chondroitin Sulfates; Dimethyl Sulfoxide; Drug Combinations; Female; Glucosamine; Humans; Hyaluronic Acid; Male; Middle Aged; Osteoarthritis, Knee; Outcome Assessment, Health Care; Sulfones

Multiple in vitro studies assessing articular tissues have indicated that glucosamine and chondroitin sulphate may possess anti-inflammatory effects, but little is known of their clinical effects in vivo. Many old horses have stiff joints, which is likely to be attributable to inflammation and therapy with these nutraceutical compounds could improve joint function.. To assess the clinical effects of a mixed supplement on the improvement of stiff gait in aged horses.. Randomised, blinded, placebo-controlled study.. A group of 24 geriatric equids (age 29 ± 4 years; mean ± s.d.) received either 3 months oral supplementation with a test compound (containing glucosamine, chondroitin sulfate and methyl sulfonyl methane), or a placebo. Kinematic outcome criteria (primary: stride length; secondary: carpal flexion, fore fetlock extension and tarsal range of motion) were objectively quantified on a treadmill at a walk and trot before and after treatment.. Stride length did not change significantly in the treated horses at the end of the trial. In the control group, carpal flexion and fore fetlock extension were significantly increased (P<0.05).. There were no indications of effect of the supplement on gait characteristics. The observations in the control group may have been due to a habituation or exercise effect. This study does not support the use of a glucosamine/chondroitin sulfate/methyl sulfonyl methane supplement to improve stiff gait in geriatric horses because of the lack of a sizeable effect. The significant changes in gait parameters in the control group may indicate the usefulness of exercise regimens in older horses.

Topics: Administration, Oral; Aging; Animal Feed; Animals; Anti-Inflammatory Agents; Chondroitin Sulfates; Diet; Dietary Supplements; Dimethyl Sulfoxide; Female; Glucosamine; Horses; Locomotion; Male; Physical Conditioning, Animal; Sulfones

This study investigates the effect of a new combination of glucosamine hydrochloride, chondroitin sulfate, methylsulfonylmethane, Harpagophytum procumbens root extract (standardized to 3% harpagoside) and bromelain extract (GCMHB) on formalin-induced damage to cartilage tissue in the rat knee joint and evaluates this combination in comparison with another combination of glucosamine hydrochloride, chondroitin sulfate and methylsulfonylmethane (GKM).. Animals in the control group were injected with formalin into the knee joint (FCG). Animals in the GCMHB-500 group were given 500mg/kg GCMHB+formalin, and those in the GKM-500 group were given 500mg/kg GKM+formalin. Finally, a healthy group (HG) was also used. GCMHB and GKM were administered to rats orally once a day for 30days. At the end of this period, the rats were sacrificed and the levels of MDA, NO, 8-OH/Gua, and tGSH in the knee joint tissue were measured. Analysis of IL-1β and TNF-α gene expression was done and the tissue was evaluated histopathologically.. MDA, NO and 8-OH/Gua levels and IL-1β and TNF-α gene expression were significantly lower in the GCMHB-500 group compared to the FCG group, whereas tGSH was significantly higher in the GCMHB-500 group than in the FCG group. No significant difference was found for the IL-1β, TNF-α and oxidant/antioxidant parameters between the GKM and FCG groups. The histopathological analysis showed that GCMHB could prevent damage to the cartilage joint, whereas GKM could not.. GCMHB may be used clinically by comparing with GKM in the treatment of osteoarthritis.

Topics: Animals; Bromelains; Cartilage; Chondroitin Sulfates; Dimethyl Sulfoxide; Disease Models, Animal; Drug Combinations; Formaldehyde; Gene Expression Regulation; Glucosamine; Harpagophytum; Interleukin-1beta; Knee Joint; Male; Osteoarthritis; Plant Extracts; Rats; Rats, Wistar; Sulfones; Tumor Necrosis Factor-alpha

The study aimed to investigate the effect of the oral administration for 15 days of either Echinacea (E) or genuphil (a composite of chondroitin sulphate, glucosamine and methyl sulfonyl methane [GCM]) nutraceutical supplements on female rat model of acute or chronic arthritis induced by bacterial outer membrane protein (OMP) from faecal flora of healthy and rheumatic humans. Anti-cyclic citrullinated peptide (anti-CCP2), C-reactive protein (CRP) and rheumatoid factor (RF) values increased (p < 0.05) in both arthritic groups as compared to normal values. The rheumatic markers anti-CCP2, CRP and RF values decreased significantly in E- and GCM-treated groups compared to arthritic none-treated acute or chronic groups. The results of RF values of GCM-treated groups in acute and chronic models decreased exhibiting no statistical difference compared with the normal value. Histological examinations of the hind paw sections revealed moderate inflammation, oedema and mild proliferation of synovial cells in acute arthritic rats and more damage to cartilage and bone with severe inflammation in chronic ones. Echinacea acute treated group showed edema with proliferated synovial membrane and partial damage in cartilage and bone. While in the E-chronic treated group, rough edge with destructed cartilage and bone existed. However, the acute GCM group revealed mild cartilage damage. But the chronic GCM group showed mild synovial cells proliferation and revealed no inflammation with mild cartilage damage edge. Results demonstrated the OMP arthropathic property and through promising light on arthritis treatment using E- or GCM, with the advantage of GMC results over that of E-. The composite GCM is needed for further studies over the dose and duration to assess its preventive effects against the bacterial OMP arthrogenicity.

Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Chondroitin Sulfates; Complex Mixtures; Dietary Supplements; Dimethyl Sulfoxide; Disease Models, Animal; Echinacea; Female; Glucosamine; Lysosomes; Plant Extracts; Rats; Stifle; Sulfones